Jasmine Naru | CANCER PROTEOMICS | Women Researcher Award

Dr. Jasmine Naru | CANCER PROTEOMICS | Women Researcher Award

Staff Scientist at Fred Hutch Cancer Center, United States

Jasmine Naru is a dedicated biological researcher with a robust background in various biological disciplines, including proteomics, molecular biology, biochemistry, and genetics. She earned her Ph.D. in Biochemistry from Panjab University, India, in 2016, and has since been associated with prestigious research institutions. Currently a Staff Scientist at the Fred Hutchinson Cancer Center in Seattle, WA, Jasmine has contributed significantly to the field of cancer research, particularly focusing on acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Her innovative research approaches aim to enhance risk stratification and therapeutic targeting for these conditions. Jasmine’s work has resulted in multiple publications in high-impact journals, showcasing her expertise and commitment to advancing the understanding of cancer biology.

Professional Profile

Education

Jasmine Naru’s educational journey reflects her commitment to biological research and academic excellence. She completed her Bachelor of Science in Life Sciences with a focus on Zoology, Botany, and Chemistry at Guru Nanak Dev University in 2006. She pursued her Master of Science in Human Genetics, graduating in 2008 from the same institution. Jasmine then advanced her studies at Panjab University, where she earned her Ph.D. in Biochemistry in 2016. Her doctoral research focused on protein profiling in retinoblastoma patients, utilizing mass spectrometry-based proteomics to identify potential biomarkers. This solid educational foundation has equipped her with the necessary knowledge and skills to excel in her research endeavors.

Professional Experience

Jasmine Naru has gained extensive professional experience in the field of biological research. She began her career as a Junior Research Fellow at the Post Graduate Institute of Medical Education and Research (PGIMER) in India in 2010. Her journey continued at Panjab University, where she served as a Junior and Senior Research Fellow until 2016. Following her academic tenure, Jasmine transitioned to the Fred Hutchinson Cancer Center in Seattle as a Postdoctoral Research Fellow, focusing on innovative cancer research projects from 2017 to 2023. Recently, she has taken on the role of Staff Scientist at Fred Hutch, where she develops novel approaches for risk stratification and therapeutic targeting in AML and MDS. Her professional trajectory showcases her dedication to advancing cancer research and her ability to lead impactful projects.

Research Interests

Jasmine Naru’s research interests are centered on advancing the understanding of hematological malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). She focuses on the development of innovative strategies for risk stratification and targeted therapy, employing proteomic and genomic approaches to identify novel biomarkers that can enhance patient outcomes. Her work encompasses the use of iPSC-derived cell lines to explore the biology of MDS and the development of immunotherapy techniques for myeloid malignancies. Jasmine is passionate about translating her research findings into clinical applications that can significantly improve the lives of patients facing these challenging diseases, making her a valuable contributor to the field of cancer research.

Research Skills

Jasmine Naru possesses a comprehensive set of research skills that enhance her capabilities as a biological researcher. Her technical proficiency includes advanced techniques in proteomics, such as mass spectrometry (ESI-MS/MS, MALDI-TOF/TOF), as well as quantitative analysis methods like iTRAQ and TMT. Jasmine is adept at using bioinformatics tools for pathway analysis and has experience in various molecular biology techniques, including PCR, ELISA, Western blotting, and flow cytometry. Additionally, she has strong analytical skills, enabling her to interpret complex data effectively. Jasmine’s multitasking abilities and collaborative approach allow her to thrive in fast-paced research environments, making her an asset to any scientific team.

Awards and Honors

Throughout her academic and professional career, Jasmine Naru has received several honors and recognitions for her contributions to the field of biological research. Notably, she was awarded the Junior Research Fellowship from the Indian Council of Medical Education and Research (ICMR) during her early research career, which provided her with essential support to pursue her doctoral studies. Her commitment to excellence is reflected in her successful publication record, with multiple first-author articles in high-impact journals. Jasmine’s research efforts have also been acknowledged through various project grants, such as the SWOG Impact Award and NIH/NIDDK funding, highlighting her contributions to advancing cancer research and her potential for future impactful work.

Conclusion

Overall, Jasmine Naru is a strong candidate for the Best Researcher Award. Her exceptional research experience in oncology, strong technical skills, and noteworthy publication record make her a highly deserving contender. Expanding her work’s breadth and obtaining more independent funding could further solidify her position as a top researcher in her field. Her dedication and scientific contributions already position her as a standout researcher with a clear impact in the scientific community.

Publication Top Note

  1. Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients
    • Authors: Pogosova-Agadjanyan, E.L., Hua, X., Othus, M., Meshinchi, S., Stirewalt, D.L.
    • Year: 2023
    • Journal: Biomarker Research
    • Volume: 11
    • Issue: 1
    • Page: 31
    • Citations: 0
  2. Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network
    • Authors: Termini, C.M., Moseley, A., Othus, M., Meshinchi, S., Stirewalt, D.L.
    • Year: 2023
    • Journal: Haematologica
    • Volume: 108
    • Issue: 11
    • Pages: 3148–3151
    • Citations: 2
  3. Coordinated missplicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome
    • Authors: Clough, C.A., Pangallo, J., Sarchi, M., Bradley, R.K., Doulatov, S.
    • Year: 2022
    • Journal: Blood
    • Volume: 139
    • Issue: 13
    • Pages: 2038–2049
    • Citations: 44
  4. AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: A SWOG report
    • Authors: Pogosova-Agadjanyan, E.L., Moseley, A., Othus, M., Meshinchi, S., Stirewalt, D.L.
    • Year: 2020
    • Journal: Biomarker Research
    • Volume: 8
    • Issue: 1
    • Page: 29
    • Citations: 23

 

 

Mrinal Ghosh | Cancer Biology | Best Researcher Award

Prof. Mrinal Ghosh | Cancer Biology | Best Researcher Award

Chief Scientist at CSIR-Indian Institute of Chemical Biology, India

Dr. Mrinal K. Ghosh is a distinguished Chief Scientist at the CSIR-Indian Institute of Chemical Biology and a Professor at AcSIR, New Delhi. With a Ph.D. in Biochemistry from the University of Calcutta, Dr. Ghosh specializes in cancer biology and inflammatory disorders. His extensive career includes leadership roles at CSIR-IICB and significant contributions to cancer research, particularly in glioma and breast cancer therapies. He has secured substantial funding for projects focusing on novel nanotechnology-based treatments and peptide therapeutics. Dr. Ghosh’s work has earned him prestigious awards such as the Bharat Vikash Award and recognition as a Fellow of the National Academy of Science & Technology. He is an active member of various scientific societies and has a robust publication record in high-impact journals. His research integrates advanced molecular biology techniques and translational medicine to address critical challenges in oncology.

Profile

Education

Dr. Mrinal K. Ghosh completed his education with a strong foundation in biochemistry and molecular biology. He earned his Ph.D. in Biochemistry from the University of Calcutta, India, where he conducted extensive research in the field from 1991 to 1997. Prior to his doctoral studies, Dr. Ghosh obtained his Master of Science degree in Biochemistry, with a focus on Molecular Biology, from the same institution in 1990. His undergraduate studies were in Chemistry, with honors, complemented by Physics and Mathematics, also at the University of Calcutta, culminating in his Bachelor of Science degree in 1988. Dr. Ghosh’s academic journey laid a solid groundwork for his subsequent research and leadership roles in cancer biology and inflammatory disorders, significantly contributing to his reputation as a leading scientist in his field.

Professional Experience

Dr. Mrinal K. Ghosh is a distinguished scientist with a remarkable career in cancer biology and inflammatory disorders. Currently serving as the Chief Scientist and Head of the Cancer Biology & Inflammatory Disorder Division at CSIR-Indian Institute of Chemical Biology (CSIR-IICB), he has been instrumental in advancing research in these fields. Prior to this role, he held positions as Senior Principal Scientist and Principal Scientist at CSIR-IICB, showcasing a trajectory of increasing responsibility. His earlier career included roles as Senior Lecturer at the Department of Biotechnology, HIT, Kolkata, and research positions at the Cleveland Clinic Foundation in the USA. Dr. Ghosh’s extensive experience includes leading significant research projects, managing research teams, and contributing to scientific advancements through his various roles and memberships in professional societies. His career is marked by his dedication to translating scientific discoveries into therapeutic innovations.

Research Interest

Dr. Mrinal K. Ghosh’s research interests focus on advancing cancer biology and inflammatory disorders through innovative biochemical and molecular approaches. His work emphasizes understanding the molecular mechanisms underlying cancer progression, particularly in glioma and breast cancer. Dr. Ghosh investigates the roles of key proteins and signaling pathways, including the p53 and Rb tumor suppressor proteins, and the ubiquitin-proteasome system in regulating cancer cell behavior. His research integrates nanotechnology and peptide therapeutics to develop novel treatment strategies, aiming to enhance the effectiveness of current therapies and overcome resistance. Additionally, Dr. Ghosh explores the implications of cancer biology in the context of stem cell research and neurodegenerative diseases. His comprehensive approach combines preclinical validation, clinical insights, and cutting-edge technology to address critical challenges in cancer treatment and provide new avenues for therapeutic interventions.

Research Skills

Dr. Mrinal K. Ghosh demonstrates exceptional research skills in the field of cancer biology and inflammatory disorders. His expertise spans molecular and cellular mechanisms, particularly in signal transduction related to cancer and stem cells. Dr. Ghosh is proficient in advanced techniques such as nanotechnology-based therapeutic systems, biomolecular target identification, and peptide therapeutic design. His research includes pre-clinical validation of therapies, focusing on glioma and breast cancer, utilizing sophisticated methods like protein modification and nanoparticle-based delivery systems. Dr. Ghosh’s ability to lead large-scale, multi-disciplinary projects is evident from his successful management of significant research grants and collaborations. His extensive publication record in high-impact journals and his role as a reviewer for leading scientific journals highlight his critical analytical skills and contribution to the scientific community. His innovative approach and comprehensive understanding of cancer biology underscore his research prowess.

Award and Recognition

Dr. Mrinal K. Ghosh has garnered significant recognition for his pioneering research in cancer biology and inflammatory disorders. His contributions have been acknowledged through numerous prestigious awards, including the Bharat Vikash Award in 2019, which honors outstanding achievements in scientific research. Dr. Ghosh is also a Fellow of the National Academy of Science & Technology (FNASc) and the Academy of Science & Technology (FAScT), reflecting his esteemed status within the scientific community. His research excellence is further underscored by his role as the Principal Investigator in several high-impact projects, such as the PAN-CSIR Cancer Research initiative and various DST-Nano Mission projects. Additionally, Dr. Ghosh has been honored with the Outstanding Scientist Award on Strategic Management and Business Strategy in 2023. These accolades, coupled with his extensive contributions to scientific literature and research, solidify his standing as a leading figure in his field.

Conclusion

Dr. Mrinal K. Ghosh is highly deserving of the Best Researcher Award due to his outstanding contributions to cancer biology and inflammatory disorders, as evidenced by his awards, extensive research funding, and high-impact publications. His leadership roles and recognition in the scientific community further underscore his excellence. Addressing areas such as enhancing international collaborations and increasing public engagement could further amplify his impact and align with broader scientific and societal goals.

Publications Top Notes

  1. MGMT in TMZ-based Glioma therapy: Multifaceted Insights and Clinical Trial Perspectives
    • Authors: Shaw R, Basu M, Karmakar S, Ghosh MK*
    • Journal: BBA – Molecular Cell Research
    • Year: 2024
    • Volume and Issue: 1871, 119673
    • Impact Factor: 5.1
    • Citations: 0
  2. Chromosomal instability (CIN) triggers immune evasion and metastatic potential in cancer through rewired STING signalling
    • Authors: Ghosh MK*, Roy S
    • Journal: Molecular Biomedicine
    • Year: 2024
    • Volume and Issue: 5(4)
    • Impact Factor: 6.0
    • Citations: 0
  3. E3 Ubiquitin Ligases in Lung Cancer: Emerging Insights and Therapeutic Opportunities
    • Authors: Basu B, Kal S, Karmakar S, Basu M, Ghosh MK*
    • Journal: Life Sciences
    • Year: 2024
    • Volume and Issue: 336, 122333
    • Impact Factor: 6.1
    • Citations: 0
  4. Carbon Nanotubes in Cancer Diagnosis and Treatment: Current Trends and Future Perspectives
    • Authors: Kumar S#, Ansari A#, Basu M#, Ghosh S#, Begam S#, Ghosh MK#*
    • Journal: Advanced Therapeutics
    • Year: 2024
    • Impact Factor: 4.6
    • Citations: 0
    • Status: In press
  5. E3 ubiquitin ligases and deubiquitinases in colorectal cancer: Emerging molecular insights and therapeutic opportunities
    • Authors: Kumar S, Basu M, Ghosh MK*
    • Journal: BBA – Molecular Cell Research
    • Year: 2024
    • Volume and Issue: 1871, 119673
    • Impact Factor: 5.1
    • Citations: 0
    • Status: In press
  6. Glioma Immunotherapy: Exploring Molecular and Clinical Frontiers
    • Authors: Ghosh MK*, Kumar S, Begam S, Ghosh S, Basu M
    • Journal: Life Sciences
    • Year: 2024
    • Impact Factor: 5.2
    • Citations: 0
    • Status: In press
  7. Glioma nanotherapy: Unleashing the synergy of dual-loaded DIM and TMZ
    • Authors: Sarkar S#, Kumar S#, Saha G, Basu M, Ghosh MK*
    • Journal: International Journal of Pharmaceutics
    • Year: 2024
    • Impact Factor: 5.3
    • Citations: 0
    • Status: Under Review (R1)
  8. Unraveling COVID-19 diagnostics: A roadmap for future pandemic
    • Authors: Kumar S, Basu M*, Chakraborty D, Ghosh P, Bajoria S, Ghosh MK*
    • Journal: Nature Cell & Sciences
    • Year: 2024
    • Status: Under Review

2023 Publications:

  1. USP7 – A crucial regulator of Cancer Hallmarks
    • Authors: Saha G, Roy S, Basu M, Ghosh MK*
    • Journal: BBA – Reviews on Cancer
    • Year: 2023
    • Volume and Issue: 1878, 188903
    • Impact Factor: 11.2
    • Citations: 10
  2. Neurological damages in COVID-19 patients: mechanisms and preventive interventions
    • Authors: Sarkar S#, Karmakar S#, Basu M, Ghosh P, Ghosh MK*
    • Journal: MedComm
    • Year: 2023
    • Volume and Issue: 4, e247,1-25
    • Impact Factor: 10.7
    • Citations: 10

 

Jaydira Del Rivero | Medical Oncology | Best Researcher Award

Dr. Jaydira Del Rivero | Medical Oncology | Best Researcher Award

MD of NCI/NIH, United States.

Dr. Jaydira Del Rivero has a robust set of research skills tailored for oncology. Her expertise includes cell culture, immunohistochemistry, CRISPR/Cas9 gene editing, and advanced microscopy. Proficient in data analysis using SPSS and R, she excels in bioinformatics for genomic data. Dr. Del Rivero is adept at experimental design, critical literature evaluation, and communicating scientific results.

Professional Profiles:

Education

Dr. Jaydira Del Rivero earned her Doctor of Medicine (MD) degree from the University of Veracruz, Faculty of Medicine “Lic. Miguel Aleman Valdez” in October 2003. She completed her Internal Medicine residency at Woodhull Medical and Mental Health Center/NYU Langone Medical Center in Brooklyn, NY, from July 2008 to June 2011. Following this, she pursued a fellowship in Endocrinology, Diabetes, and Metabolism at the Inter-Institute Adult Endocrine Training Program at the National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, from July 2011 to June 2014. Dr. Del Rivero further specialized in Medical Oncology through a fellowship at the National Cancer Institute, National Institutes of Health, Bethesda, MD, from July 2015 to June 2017. Her extensive training reflects her deep commitment to advancing in both endocrinology and oncology.

Professional Experience

Dr. Jaydira Del Rivero has held several notable positions in the medical field. She began her career as a Medical Officer at the National Institute of Child Health and Human Development from August 2014 to June 2015, where she focused on endocrine research. Following her fellowship in Medical Oncology, she joined the National Cancer Institute (NCI) as a Clinical Fellow in the Medical Oncology Branch from July 2015 to June 2017. Since 2017, Dr. Del Rivero has been a Medical Oncologist at the NCI, specializing in the treatment and research of cancer. Her role involves clinical practice, patient management, and contributing to ongoing research efforts. Dr. Del Rivero’s work is pivotal in advancing the understanding and treatment of oncology-related conditions.

Research Interest

Dr. Jaydira Del Rivero’s research interests are centered around oncology, with a particular focus on advancing the understanding and treatment of cancer. Her work primarily explores endocrine-related malignancies, including the development of novel therapeutic strategies and treatment protocols. Dr. Del Rivero is involved in researching the mechanisms of cancer progression and resistance to treatments, aiming to improve patient outcomes through innovative approaches. Her research also encompasses the evaluation of new drugs and treatment regimens, with a commitment to integrating clinical findings with experimental data to enhance therapeutic efficacy. Through her work at the National Cancer Institute, she contributes to cutting-edge studies that aim to address critical challenges in cancer care and therapy.

Award and Honors

Dr. Jaydira Del Rivero has received several notable awards and honors for her contributions to oncology research. She was recognized with the prestigious NCI Director’s Award in 2021 for her exceptional work in cancer research and her commitment to advancing treatment options. In 2019, she earned the American Association for Cancer Research (AACR) Scholar Award, which acknowledged her innovative research on endocrine-related cancers. Additionally, Dr. Del Rivero was honored with the National Cancer Institute’s Outstanding Research Award in 2018 for her impactful studies on novel therapeutic strategies. Her achievements reflect her dedication to improving cancer care and her significant contributions to the field of oncology.

 Research Skills

Dr. Jaydira Del Rivero possesses advanced research skills essential for her work in oncology. She is proficient in various laboratory techniques including cell culture, immunohistochemistry, and molecular cloning. Her expertise extends to cutting-edge methods such as CRISPR/Cas9 gene editing and advanced microscopy techniques. Dr. Del Rivero is skilled in data analysis and statistical software such as SPSS and R, which she utilizes for interpreting complex research data. She also has experience with bioinformatics tools for genomic data analysis, enabling her to identify novel biomarkers and therapeutic targets. Her research skills are complemented by a strong ability to design and conduct experiments, critically evaluate scientific literature, and effectively communicate findings through publications and presentations.

Publications
  1. Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity
    Authors: E Wong, LS Rosen, M Mulay, A VanVugt, M Dinolfo, C Tomoda, …
    Journal: Thyroid
    Year: 2007
    Volume/Issue: 17 (4), 351-355
    Citations: 238
  2. The Bethesda handbook of clinical oncology
    Authors: J Abraham, JL Gulley
    Publisher: Lippincott Williams & Wilkins
    Year: 2022
    Citations: 158
  3. Anti–PD-L1 treatment induced central diabetes insipidus
    Authors: C Zhao, SH Tella, J Del Rivero, A Kommalapati, I Ebenuwa, J Gulley, …
    Journal: The Journal of Clinical Endocrinology & Metabolism
    Year: 2018
    Volume/Issue: 103 (2), 365-369
    Citations: 104
  4. Tyrosine kinase inhibitor–induced thyroid disorders: a review and hypothesis
    Authors: N Makita, T Iiri
    Journal: Thyroid
    Year: 2013
    Volume/Issue: 23 (2), 151-159
    Citations: 99
  5. Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors
    Authors: AM Rosenberg, P Friedmann, J Del Rivero, SK Libutti, AM Laird
    Journal: Surgery
    Year: 2016
    Volume/Issue: 159 (1), 302-310
    Citations: 93
  6. Phenotypic and genotypic characterization and treatment of a cohort with familial tumoral calcinosis/hyperostosis‐hyperphosphatemia syndrome
    Authors: MS Ramnitz, P Gourh, R Goldbach‐Mansky, F Wodajo, S Ichikawa, …
    Journal: Journal of Bone and Mineral Research
    Year: 2016
    Volume/Issue: 31 (10), 1845-1854
    Citations: 87
  7. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and management of metastatic and/or unresectable pheochromocytoma and paraganglioma
    Authors: L Fishbein, J Del Rivero, T Else, JR Howe, SL Asa, DL Cohen, PLM Dahia, …
    Journal: Pancreas
    Year: 2021
    Volume/Issue: 50 (4), 469-493
    Citations: 77
  8. Novel insights into the polycythemia–paraganglioma–somatostatinoma syndrome
    Authors: R Därr, J Nambuba, J Del Rivero, I Janssen, M Merino, M Todorovic, …
    Journal: Endocrine-Related Cancer
    Year: 2016
    Volume/Issue: 23 (12), 899-908
    Citations: 76
  9. Endocrine‐related adverse events related to immune checkpoint inhibitors: Proposed algorithms for management
    Authors: J Del Rivero, LM Cordes, J Klubo‐Gwiezdzinska, RA Madan, LK Nieman, …
    Journal: The Oncologist
    Year: 2020
    Volume/Issue: 25 (4), 290-300
    Citations: 72
  10. Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report
    Authors: JE Faris, AF Moore, GH Daniels
    Journal: Thyroid
    Year: 2007
    Volume/Issue: 17 (11), 1147-1149
    Citations: 72